Financing in the pharmaceutical industry is frequent, focusing on cell therapy, ADC, genetic testing and other fields

Since March, financing in the domestic pharmaceutical industry has been frequent, involving a large number of pharmaceutical companies such as Yilian Bio, Likai Technology, Dipu Diagnostics, Aoran Bio, etc.
, mainly focusing on cell therapy, ADC, genetic testing, medical devices and other fields
.
Yilian Bio recently announced that the company has completed a US$70 million Series B financing.
This round of financing was jointly led by LYFE Capital (Zhouling Capital) and Qiming Venture Capital, Legend Capital, Zhengxin Valley Capital and Honghui Fund (HLC) Wait for follow-up
.
The funds raised will be mainly used for the clinical trial development of the company's next-generation ADC product pipeline and the early development of new conjugated drugs
.
On March 15th, Yiyao Technology announced that it has completed an angel + round of financing of 10 million yuan from Xiantong Capital
.
This round of funds will be used for the development of the desktop version of Lingsu drug development system, to accelerate the rapid advancement of the company's pipeline in the direction of life extension and metabolic diseases, to improve the cloud computing platform, the construction of innovative R&D laboratories, and to recruit teams, etc.
aspect
.
On the same day, Moting Medical, which is deeply involved in the field of domestic ophthalmic medical devices, announced the completion of tens of millions of yuan in A+ round of financing.
This round of financing was completed by BV Baidu Ventures
.
The funds raised in this round will be used for product line expansion and market promotion
.
In mid-March, Likai Technology announced that it had completed a B+ round of financing of more than 200 million yuan.
This round of financing was jointly led by Shenzhen Venture Capital and Lingang Science and Technology Venture Capital, and followed by Zhang Jiang Haoheng, Shanghai Science and Technology Fund, and Betta Fund.
The old shareholder Hengxu Capital made additional investment
.
The company focuses on R&D, production and sales of neurointerventional implantable medical device products
.
On March 14, Dipu Diagnostics announced the completion of a Series B financing of over 100 million yuan
.
This round of financing was led by Shanghai Pudi (Jingxu Venture Capital), followed by Tai Kun Fund and Rushan Growth Ventures (Rushan Capital)
.
The funds raised in this round will be mainly used for the research and development, production, registration and application of new high-end genetic testing products, as well as the comprehensive promotion of clinical application strategies.

.
Also on the 14th, Yudao Bio, which focuses on the development of small molecule drugs with allosteric mechanisms, recently announced the completion of a $40 million A+ round of financing.
This financing was led by Yuansheng Capital, co-led by Hengxu Capital, and old shareholder Source Code Capital.
, Kunlun Capital, Jingwei Ventures, and Northern Lights Ventures continued to overweight
.
On March 10th, Kaidi Medical, which is committed to the development of cell therapy drugs, announced that it has completed nearly 100 million yuan in A and A+ rounds of financing
.
This round of financing is jointly invested by "Longmen Capital" and "Kangyuan Huiying", which is used to deepen cooperation with strategic partners such as Proton Bio, and accelerate the process of Sino-US IND application and POC clinical verification of the company's core pipelines.
carry out
.
AAV gene therapy new drug research and development company Jinweike recently completed a Pre-A round of financing of tens of millions of yuan
.
This round of financing was jointly invested by Ruijing Investment, Yingke Capital, East Lake High-tech, Ming Capital, Sichuan Huishu and others
.
The funds raised in this round will be used to advance the IND filing of the company's pipeline
.
On March 5, Unas announced the completion of 20 million yuan in Series A financing.
This round of financing will be mainly used to promote the clinical transformation of Unas artificial kidney and artificial liver support system-related blood purification products, and to accelerate Unas virus.
, the research and development progress of technologies related to tumors, metabolic diseases and immune diseases, as well as the transformation of GMP workshops, the construction of talent echelons, strengthening external business cooperation and replenishing working capital
.
At the beginning of March, Oran Bio announced the successful completion of the C round of financing of hundreds of millions of RMB
.
This financing was led by Morningside Ventures, followed by Shanlan Capital, Silicon Port Capital, Kanghua Biotechnology, and the original shareholder Bangqin Capital, etc.
continued to make additional investments.
The funds raised in this round will be mainly used for the registration of molecular diagnostic clinical products , automatic production line expansion, product commercialization promotion and new product development,
etc.
On March 2, Huayi Lejian, a gene therapy drug research and development company, announced the completion of a series A financing of several hundred million yuan
.
This round of financing was led by Sequoia China, followed by Sunshine Insurance, Qingpine Capital, and Beijing Life Garden Venture Capital Fund.
The old shareholders, Everbright Holdings, Guoyu Yingfu, and Huaxing Capital continued to support
.
Continuing, this round of financing will be mainly used to advance the production, registration, clinical and research of the company's lead gene therapy products, as well as to accelerate the company's development of other products targeting the liver and targeting nerves
.
On March 1, Spring Pharma announced the completion of the A round of financing with a scale of 100 million yuan.
The leading investor of this round of financing, Dongfang Fuhai, and the partner of Yichuang Investment, Zhejiang Fuju participated in the investment
.
The company focuses on providing professional services for the whole process of clinical research for innovative pharmaceutical and device companies
.
In addition, in March, Honghai MicroPort completed tens of millions of yuan in Series A financing, led by China Development and Qihang Fund
.
This round of financing is mainly used for the research and development of cerebral vein thrombectomy stents, intracranial vein stents and other products
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.